Nuance Pharma Hosts National Investigators' Meeting in Shanghai for the STG320 (Actair®) Phase III Clinical Study (REACH Study)

September 10, 2026 — The National Investigators' Meeting for the Phase III clinical study (REACH Study) of STG320 (Actair®) for the treatment of house dust mite–associated allergic rhinitis, hosted by Nuance Pharma, was grandly convened in Shanghai, China. Professor Li Jing of the First Affiliated Hospital of Guangzhou Medical University, the lead coordinating site of the study, together with research teams from 35 study centers across China, the senior director of MA & CE of STALLERGENES GREER, Dr. Jaime SÁNCHEZ LÓPEZ, the CEO of Nuance Pharma, Mark Lotter, and the COO of Nuance Pharma, Charlie Chen, attended the event both in person and online, offering constructive input for the REACH Phase III clinical study.

Group Photo of The Attendees

Actair® is a sublingual tablet for the treatment of allergic rhinitis caused by house dust mites, and is currently commercialized in 25 countries/regions.

01 Opening Remarks

The 1st Affiliated Hospital of Guangzhou Medical University / Professor / Li Jing

Professor Li Jing delivered the opening remarks on behalf of Academician Zhong Nanshan and in his capacity as Principal Investigator of the study. Professor Li said that, following multiple rounds of careful deliberation and discussion on the clinical trial protocol in the earlier stages, he was delighted to see the study officially launched through the concerted efforts of all parties. The study is co-developed by Nuance Pharma and STALLERGENES GREER, a renowned French company with long-standing dedication to the field of allergy. Professor Li also noted that the incidence of allergic rhinitis has been rising year by year, with house dust mite allergens accounting for a relatively high proportion; against this backdrop, new drug development is of great significance in providing patients with more treatment options. In closing, Professor Li expressed his earnest expectations for the smooth progress of the study.

The Nuance Pharma / Chief Executive Officer / Mr. Mark Lotter 

Mr. Mark Lotter said: "Development in the respiratory and allergy fields is Nuance Pharma's core business. Actair® is a key product of STALLERGENES GREER, a century-old company, for the treatment of allergic rhinitis, and has been widely commercialized worldwide; to date, it has received marketing approval in 25 countries and in Macao, China. In addition, the product has been successfully made available through special access pathways in Boao Lecheng, Hainan, and in the Greater Bay Area — an important step toward benefiting Chinese patients. Based on Actair®'s product profile, Nuance Pharma is fully confident in its development prospects. We believe that, under the leadership of Academician Zhong and Professor Li, Nuance Pharma and STALLERGENES GREER will work closely with all study centers to jointly advance this important clinical study, striving to reach its goals as early as possible so that Actair® can benefit a broad patient population at the earliest date."

The STALLERGENES GREER / Senior Director of MA & CE / Dr. Jaime SÁNCHEZ LÓPEZ

Dr. Jaime SÁNCHEZ LÓPEZ, representing STALLERGENES GREER, first extended his heartfelt thanks to all study centers participating in this important study. He noted that conducting the REACH Phase III clinical study in China is an important milestone in the global development of Actair®, marking another solid step toward the shared goal of "improving the quality of life of patients with allergic respiratory diseases."

02 Special Presentation

The 1st Affiliated Hospital of Guangzhou Medical University / Dr. Wang Wanjun

Dr. Wang Wanjun, an investigator from the First Affiliated Hospital of Guangzhou Medical University, shared valuable experience in improving trial participant adherence, compliance and security, as well as further reflections specific to this study.

03 Discussion and Summary

During the discussion session of the investigators' meeting, attendees engaged in lively discussion and extensive sharing around key topics, including an in-depth understanding of the study protocol and trial execution. At the close of the meeting, Professor Li Jing once again expressed his firm confidence in the REACH Phase III clinical study and called on all study centers to work together in concert to jointly ensure the smooth conduct of the study.

(End)